前列腺癌间歇性内分泌治疗进展

罗文强; 张心如

doi:10.13201/j.issn.1001-1420.2017.09.019

前列腺癌间歇性内分泌治疗进展

罗文强,
张心如^,

- 上海交通大学附属第六人民医院泌尿外科(上海, 200233)

详细信息

通讯作者: 张心如,E-mail:13061764323@163.com

中图分类号: R737.25

收稿日期: 2017-05-12

Progression of intermittent androgen deprivation for prostate cancer

LUO Wenqiang,
ZHANG Xinru^,

- Department of Urology, Sixth People's Hospital Affiliatedto ShanghaiJiao Tong University, Shanghai, 200233, China

More Information

Corresponding author: ZHANG Xinru, E-mail: 13061764323@163.com

Received Date: 12 May 2017

摘要

摘要: 近年来前列腺癌在中国的发病率逐年上升，尤其对于超过60岁的男性。世界范围内，前列腺癌发病率在男性所有恶性肿瘤中位居第二。临床上前列腺癌主要治疗方法为根治性手术或放射治疗。而对于转移性前列腺癌或无法行根治性前列腺切除术和根治放射治疗的患者，内分泌治疗为首选治疗。而且近年来前列腺癌间歇性内分泌治疗的重要性及认可度逐渐提高，本文将对前列腺癌间歇性内分泌治疗最新的研究进展作一总结，以期为前列腺癌内分泌治疗提供新的思路。
- 前列腺癌 /
- 间歇性 /
- 内分泌治疗
Abstract: In recent years, the morbidity of prostate cancer in China has increased year by year, especially for old men above 60 years old.Worldwide, it reached the second place of all malignant tumors in men.Clinically, the main treatment for prostate cancer is radical surgery or radiotherapy.Androgen deprivation therapy is the first choice for patients with metastatic prostate cancer or who are unable to undergo radical prostatectomy or radical radiotherapy.And in recent years the importance of intermittent androgen deprivation has been recognised by most surgeons.In order to provide some new ideas for the treatment of prostate cancer, we collected and summarized the latest research results.
- prostate cancer /
- intermittent /
- androgen deprivation therapy

HTML全文

参考文献(39)

[1]	Heidenreich A, Bastian P J, Bellmunt J, et al.EAUguidelines on prostate cancer.part 1:screening, diagnosis, and local treatment with curative intentupdate 2013[J].Eur Urol, 2014, 65 (1):124-137.
[2]	Center M M, Jemal A, Lortet-Tieulent J, et al.Internatiaoal variation in prostate cancer incidence and mortality rates[J].Eur Urol, 2012, 61 (6):1079-1092.
[3]	齐金蕾, 王黎君, 周脉耕, 等.1990-2013年中国男性前列腺癌疾病负担分析[J].中华流行病学杂志, 2016, 37 (6):778-782.
[4]	Schrder F, Crawford E D, Axcrona K, et al.Androgen deprivation therapy:past, present and future[J].BJUInt, 2012, 109 Suppl 6:1-12.
[5]	Huggins C, Hodges C V.Studies on prostatic cancer:I.The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate:1941[J].J Urol, 2002, 168 (1):9-12.
[6]	Klotz L H, Herr H W, Morse M J, et al.Intermittent endocrine therapy for advanced prostate cancer[J].Cancer, 1986, 58 (11):2546-2550.
[7]	Heidenreich A, Aus G, Bolla M, et al.EAU guidelines on prostate cancer[J].Eur Urol, 2008, 53 (1):68-80.
[8]	Crook J M, O'Callaghan C J, Duncan G, et al.Intermittent androgen suppression for rising PSA level after radiotherapy[J].N Engl J Med, 2012, 367 (10):895-903.
[9]	Hussain M, Tangen C M, Berry D L, et al.Intermittent versus continuous androgen deprivation in prostate cancer[J].N Engl J Med, 2013, 368 (14):1314-1325.
[10]	Calais da Silva F, Calais da Silva F M, Goncalves F, et al.Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade:results from a randomised phase 3study by the South European Uroncological Group[J].Eur Urol, 2014, 66 (2):232-239.
[11]	Salonen A J, Taari K, Ala-Opas M, et al.The FinnProstate Study VII:intermittent versus continuous androgen deprivation in patients with advanced prostate cancer[J].J Urol, 2012, 187 (6):2074-2081.
[12]	Schulman C, Cornel E, Matveev V, et al.Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer:A Phase 3b Randomised Study (ICELAND)[J].Eur Urol, 2016, 69 (4):720-727.
[13]	Irani J, Celhay O, Hubert J, et al.Continuous versus six months a year maximal androgen blockade in the management of prostate cancer:a randomised study[J].Eur Urol, 2008, 54 (2):382-391.
[14]	Heidenreich A, Bastian P J, Bellmunt J, et al.EAUguidelines on prostate cancer.Part II:Treatment of advanced, relapsing, and castration-resistant prostate cancer[J].Eur Urol, 2014, 65 (2):467-79.
[15]	Saad F, Chi K N, Finelli A, et al.The 2015 CUA-CUOGGuidelines for the management of castration-resistant prostate cancer (CRPC)[J].Can Urol Assoc J, 2015, 9 (3-4):90-96.
[16]	胡斐, 朱雅慧, 许青.去势抵抗性前列腺癌化疗耐药机制的研究进展[J].现代肿瘤医学, 2015, 23 (21):3194-3196.
[17]	Rennie P S, Bruchovsky N, Coldman A J.Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes[J].J Steroid Biochem Mol Biol, 1990, 37 (6):843-847.
[18]	Bladou F, Vessella R L, Buhler K R, et al.Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration[J].Int J Cancer, 1996, 67 (6):785-790.
[19]	Feldman B J, Feldman D.The development of androgenindependent prostate cancer[J].Nat Rev Cancer, 2001, 1 (1):34-45.
[20]	Ku J Y, Lee J Z, Ha H K.The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment[J].Korean J Urol, 2015, 56 (10):689-694.
[21]	de Leval J, Boca P, Yousef E, et al.Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer:results of a prospective randomized multicenter trial[J].Clin Prostate Cancer, 2002, 1 (3):163-171.
[22]	Tao Y, Guo Q, Aihara K.A partial differential equation model and its reduction to an ordinary differential equation model for prostate tumor growth under intermittent hormone therapy[J].J Math Biol, 2014, 69 (4):817-838.
[23]	Morgans A K, Fan K H, Koyama T, et al.Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy[J].J Urol, 2015, 193 (4):1226-1231.
[24]	Jin C, Fan Y, Meng Y, et al.A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients[J].Prostate Cancer Prostatic Dis, 2016, 19 (4):333-339.
[25]	Muresanu H.Benefits of intermittent/continuous androgen deprivation in patients with advanced prostate cancer[J].Clujul Med, 2016, 89 (3):419-422.
[26]	Theyer G, Holub S, Olszewski U, et al.Measurement of bone turnover in prostate cancer patients receiving intermittent androgen suppression therapy[J].Open Access J Urol, 2010, 2:155-159.
[27]	Spry N A, Galvao D A, Davies R.Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density:results of a 33-month observational study[J].BJU Int, 2009, 104 (6):806-812.
[28]	Tsai H T, Pfeiffer R M, Philips G K.Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer Patients:A Population Based Study[J].J Urol, 2017, 197 (5):1251-1257.
[29]	Rezaei M M, Rezaei M M, Ghoreifi A, et al.Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy[J].Can Urol Assoc J, 2016, 10 (9-10):E300-305.
[30]	贾东升, 杨全成, 王彤, 等.前列腺癌内分泌治疗副作用的初步探讨[J].中国医学创新, 2010, 7 (32):188-189.
[31]	Sanchez-Salas R, Olivier F, Prapotnich D, et al.First off-time treatment prostate-specific antigen kinetics predicts survival in intermittent androgen deprivation for prostate cancer[J].Prostate, 2016, 76 (1):13-21.
[32]	Kuo K F, Hunter-Merrill R, Gulati R, et al.Relationships between times to testosterone and prostatespecific antigen rises during the first off treatment interval of intermittent androgen deprivation are prognostic for castrationresistance in men with non-metastatic prostate cancer[J].Clin Genitourin Cancer, 2015, 13 (1):10-16.
[33]	Sciarra A, Cattarino S, Gentilucci A, et al.Predictors for response to intermittent androgen deprivation (IAD) in prostate cancer cases with biochemical progression after surgery[J].Urol Oncol, 2013, 31 (5):607-614.
[34]	Klotz L, O'Callaghan C, Ding K, et al.Nadir testosterone within first year of androgen deprivation therapy (ADT) predicts for time to castration-resistant progression:a secondary analysis of the PR-7trial of intermittent versus continuous ADT[J].J Clin Oncol, 2015, 33 (10):1151-1157.
[35]	Tunn U W, Canepa G, Hillger H, et al.Intermittent androgen deprivation in patients with PSA-relapse after radical prostatectomy-final results of a European randomized prospective phase-Ⅲclinical trial AUO study AP 06/95, EC 507[J].J Urol, 2007, 177 (4):201.
[36]	Calais da Silva F M, Calais da Silva F, Bono A, et al.PhaseⅢstudy of intermittent MAB vs continuous MAB[J].J Urol, 2011, 185 (4):288.
[37]	Gleave M, Klotz L, Taneja S S.The continued debate:intermittent vs.continuous hormonal ablation for metastatic prostate cancer[J].Urol Oncol, 2009, 27 (1):81-86.
[38]	那彦群.中国泌尿外科疾病诊断治疗指南:2014版[M].北京:北京人民卫生出版社, 2013:74.
[39]	Hirata Y, Morino K, Akakura K, et al.Intermittent Androgen Suppression:Estimating Parameters for Individual Patients Based on Initial PSA Data in Response to Androgen Deprivation Therapy[J].PLoS One, 2015, 10 (6):e0130372.